Form 4: Sutro Biopharma Director Acquires Stock Options
Statement of Changes in Beneficial Ownership
Sutro Biopharma, Inc. director Jon Marc Wigginton was granted stock options for 10,000 shares of common stock.
Summary
- Jon Marc Wigginton, a Director at Sutro Biopharma, Inc., was granted stock options on June 5, 2026.
- The options are for 10,000 shares of common stock with an exercise price of $26.09 per share.
- These options are set to vest monthly, with 8.33% of the total award vesting each month.
- The first tranche is scheduled to vest on July 5, 2026, and the award will be fully vested by June 5, 2027, or the date of the issuer's 2027 annual stockholders meeting, whichever comes first.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard compensation event for a director rather than a significant financial event for the company.
Positives
- Director Wigginton's acquisition of stock options aligns his interests with those of other shareholders, potentially signaling confidence in the company's future performance.
- The vesting schedule is structured to incentivize continued service and performance over a defined period.
Future Outlook
The stock options granted are subject to vesting over time, indicating a forward-looking incentive tied to continued service and company performance.
Industry Context
StockSavvy.ai notes that the granting of stock options to directors is a common practice in the biopharmaceutical industry as a method to attract, retain, and incentivize key leadership, aligning their financial success with that of the company and its shareholders.
Stakeholder Impact
- Shareholders: The alignment of director incentives with shareholder interests may be viewed positively.
- Employees: The granting of options to a director can be seen as part of the broader compensation strategy for leadership within the company.
Next Steps
- Monthly vesting of stock options commencing July 5, 2026.
- Full vesting of stock options by June 5, 2027, or the 2027 annual stockholders meeting.
Key Dates
| Date | Description |
|---|---|
| 06/05/2026 | Earliest transaction date and grant date of stock options. |
| 07/05/2026 | Date of the first vesting tranche for the stock options. |
| 06/05/2027 | Full vesting date of the stock options, or earlier if the 2027 annual stockholders meeting occurs before this date. |
| 06/09/2026 | Date the statement was signed. |
Keywords
Sutro Biopharma, STRO, Form 4, Stock Options, Insider Trading, Director Compensation, Beneficial Ownership, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.